PTO/SB/30 (08-03)-006. OMB 068-0031

Approved for use through 07/31/2006. OMB 068 0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Panegyork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons ar	e required to respon	d to a conection of the	ATTICLE IT CONTROL TO THE CONTROL THE TIESE	
Request	Application No	umber 1	0/073,135	
For Continued Examination (RCE)	Filing Date	F	ebruary 13, 2002	
Transmittal St	First Named I	nventor A	kemichi BABA	
JUL 0 8 2005 G	Art Unit	1	636	
Address to: Mail Stop RCE	Examiner Nar	ne C	Celine X. Qian	
Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	Attomey Dock	cet Number 0	10541A	
This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.				
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.				
1. Submission required under 37 C.F.R. § 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If				
applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).				
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
ii Consider the arguments in the Appeal Brief or Rely Brief previously filed on				
iii Other				
b. Enclosed i Namendment/Reply iii. Information Disclosure Statement (IDS)				
	Affidavit(s)/Declaration(s)  iv. Other <u>Petition for Extension of Time</u>			
Miscellaneous     Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a				
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)				
b Other				
3. Fees The RCE fee under 37 C.F.R. § 1.17 (e) is required by 37 C.F.R. § 1.114 when RCE is filed.				
a. Check in the amount of \$620.00 = \$395.00 (RCE) + \$225.00 (EOT) enclosed				
i RCE fee required under 37 C.F.R. § 1.  ii Extension of time fee (37 C.F.R. §§ 1.1	7//16/6003 UDETENET 00000054 100/3133			
iii Other	oo ana 1.17)	01 FC:2801	395.00 OP	
b. The Director is hereby authorized to charge any additional fees in connection with filing of this paper or credit any overpayments,				
to Deposit Account No. 50-2866.  C. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name (Print/Type) Nicolas E. Seckel	Registration No. (Attorney/Agent) 44,373			
Signature Michan Mukel	Date	July 8, 2	005	
CERTIFICATE OF MAILING OR TRANSMISSION				
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.				
Name (Print/Type)				
Signature	<u></u>	Date		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Akemichi BABA et al.

Confirmation No.: 5435

Serial Number: 10/073,135

Group Art Unit: 1636

Filed: February 13, 2002

Examiner: QIAN, CELINE X.

For:

NON-HUMAN ANIMAL DEFICIENT IN FUNCTION OF PITUITARY ADENYLATE

CYCLASE-ACTIVATING POLYPEPTIDE GENE

Atty. Docket No.: 010541A Customer No.: 38834

## AMENDMENT UNDER 37 C.F.R. 1.114

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

July 8, 2005

Further to the Amendment filed February 8, 2005 in response to the Office Action dated September 8, 2004, to the Advisory Action dated February 28, 2005, and to the Notice of Appeal filed March 8, 2005, Applicants respectfully request that the application be amended as follows, and that the rejection of record be reconsidered in view of the following remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

Copies of eight publications discussed in the Remarks are submitted with this paper as new evidence for consideration.

Also, a Request for Continued Examination and a Petition for a two-month extension of time for response are submitted with this paper.